Assessment of Efficacy of KAN-JANG® in Mild COVID-19
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The complexity of COVID-19 suggests a potential need for a range of therapies, including
antiviral agents, immunostimulants, immunosuppressants, adaptogens, and anticoagulants. In
this context, implementation of polyvalency drugs, which exhibit a wide range of biological
activities and multitarget effects that is common for herbal medicines and specifically for
Kan Jang, the fixed combination of Andrographis paniculata (Burm. F.) Wall. ex. Nees and
Eleutherococcus senticosus (Rupr. & Maxim.) Maxim which are known to exhibit antiviral,
immunomodulatory, and anti-inflammatory effects and clinical efficacy in the respiratory
tract of patients with infectious diseases. The purpose of this study is to provide
scientific evidence on the effectiveness of Kan Jang for the treatment of mild COVID-19. We
hypothesize that Kan Jang will have superior efficacy in amelioration COVID symptoms compared
to placebo with a comparable safety profile to placebo. We hypothesize that Kan Jang will
increase patients' recovery rate and decrease the duration of illness.
The objective of the study is to assess the efficacy and tolerability of adjuvant treatment
with Kan Jang for alleviating the severity of inflammatory symptoms (headache, loss of smell,
gustatory dysfunction, rhinorrhea, nasal congestions, cough, sore throat, asthenia, myalgia,
and fever) and shortening of their duration in mild COVID-19 patients.